External guide sequence technology: a path to development of novel antimicrobial therapeutics

被引:24
|
作者
Davies-Sala, Carol [1 ,2 ,3 ]
Soler-Bistue, Alfonso [1 ,2 ,3 ]
Bonomo, Robert A. [4 ]
Zorreguieta, Angeles [1 ,2 ]
Tolmasky, Marcelo E. [3 ]
机构
[1] Univ Buenos Aires, Fdn Inst Leloir, IIBBA CONICET, RA-1053 Buenos Aires, DF, Argentina
[2] Univ Buenos Aires, FCEyN, RA-1053 Buenos Aires, DF, Argentina
[3] Calif State Univ Fullerton, Ctr Appl Biotechnol Studies, Coll Nat Sci & Math, Fullerton, CA 92634 USA
[4] Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA
来源
关键词
antisense; external guide sequence; RNase P; drug design; antimicrobials; RNASE P RIBOZYMES; CYTOMEGALOVIRUS GENE-EXPRESSION; MORPHOLINO OLIGOMER CONJUGATE; ESCHERICHIA-COLI; MESSENGER-RNA; RIBONUCLEASE-P; IN-VITRO; EFFECTIVE INHIBITION; TARGETED CLEAVAGE; III SECRETION;
D O I
10.1111/nyas.12755
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
RNase P is a ribozyme originally identified for its role in maturation of tRNAs by cleavage of precursor tRNAs (pre-tRNAs) at the 5'-end termini. RNase P is a ribonucleoprotein consisting of a catalytic RNA molecule and, depending on the organism, one or more cofactor proteins. The site of cleavage of a pre-tRNA is identified by its tertiary structure; and any RNA molecule can be cleaved by RNase P as long as the RNA forms a duplex that resembles the regional structure in the pre-tRNA. When the antisense sequence that forms the duplex with the strand that is subsequently cleaved by RNase P is in a separate molecule, it is called an external guide sequence (EGS). These fundamental observations are the basis for EGS technology, which consists of inhibiting gene expression by utilizing an EGS that elicits RNase P-mediated cleavage of a target mRNA molecule. EGS technology has been used to inhibit expression of a wide variety of genes, and may help development of novel treatments of diseases, including multidrug-resistant bacterial and viral infections.
引用
收藏
页码:98 / 110
页数:13
相关论文
共 50 条
  • [1] Challenges and opportunities in the development of novel antimicrobial therapeutics for cystic fibrosis
    Barton, Thomas E.
    Frost, Frederick
    Fothergill, Joanne L.
    Neill, Daniel R.
    JOURNAL OF MEDICAL MICROBIOLOGY, 2022, 71 (12)
  • [2] Precision antimicrobial therapeutics: the path of least resistance?
    Spaulding, Caitlin N.
    Klein, Roger D.
    Schreiber, Henry L.
    Janetka, James W.
    Hultgren, Scott J.
    NPJ BIOFILMS AND MICROBIOMES, 2018, 4
  • [3] Precision antimicrobial therapeutics: the path of least resistance?
    Caitlin N. Spaulding
    Roger D. Klein
    Henry L. Schreiber
    James W. Janetka
    Scott J. Hultgren
    npj Biofilms and Microbiomes, 4
  • [4] Innovir, U Penn to study agricultural uses of external guide sequence technology
    不详
    BIOTECHNOLOGY LAW REPORT, 1996, 15 (03): : 454 - 454
  • [5] Responding to Antimicrobial Resistance with Novel Therapeutics
    Teitzel, Gail
    TRENDS IN MICROBIOLOGY, 2019, 27 (04) : 285 - 286
  • [6] Development of of a Novel Food Antimicrobial Technology: Application of Bacteriophages
    Yamaki, Shogo
    Yamazaki, Koji
    JOURNAL OF THE JAPANESE SOCIETY FOR FOOD SCIENCE AND TECHNOLOGY-NIPPON SHOKUHIN KAGAKU KOGAKU KAISHI, 2020, 67 (10): : 352 - 359
  • [7] Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?
    Sanacora, Gerard
    Schatzberg, Alan F.
    NEUROPSYCHOPHARMACOLOGY, 2015, 40 (02) : 259 - 267
  • [8] Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?
    Gerard Sanacora
    Alan F Schatzberg
    Neuropsychopharmacology, 2015, 40 : 259 - 267
  • [9] The impact of the completed human genome sequence on the development of novel therapeutics for human disease
    Austin, CP
    ANNUAL REVIEW OF MEDICINE, 2004, 55 : 1 - 13
  • [10] Erratum: Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?
    Gerard Sanacora
    Alan F Schatzberg
    Neuropsychopharmacology, 2015, 40 : 1307 - 1307